The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index; 11 of the 24 sources its claims cite were checked for support.
GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings
Open accessAbstract
INTRODUCTION: The diagnosis of tuberculous lymphadenitis (TBL) remains challenging. The routinely used methods (cytology and smear microscopy) have sub-optimal sensitivity. Recently, WHO recommends GeneXpert to be used as the initial diagnostic test in patients suspected of having extra-pulmonary tuberculosis (EPTB). However, this was a conditional recommendation due to very low-quality evidence available and more studies are needed. In this study we evaluated the performance of Xpert for the diagnosis of TBL on concentrated fine needle aspirates (FNA) in Southwest Ethiopia. METHODS: FNA was collected from presumptive TBL cases. Two smears were prepared from each aspirate and processed for cytology and conventional microscopy. The remaining aspirate was treated with N-acetyl-L-cysteine-NaOH and centrifuged for 15minutes at 3000g. The concentrated sediment was used for culture and Xpert test. Capilia TB-Neo test was used to differentiate M. tuberculosis complex (MTBC) from non-tuberculous mycobacteria (NTM). Composite bacteriological methods (culture and/or smear microscopy) were considered as a reference standard. RESULT: Out of 143 enrolled suspects, 64.3% (92/143) were confirmed TBL cases by the composite reference standard (CRS). Xpert detected M. tuberculosis complex (MTBC) in 60.1% (86/143) of the presumptive TBL cases. The sensitivity of Xpert compared to CRS was 87.8% [95% CI: 81.0-94.5] and specificity 91.1% [95% CI: 82.8-99.4]. The sensitivity was 27.8% for smear microscopy and 80% for cytology compared to CRS. Cytology showed the lowest specificity (57.8%). Xpert was positive in 4 out of 45 culture- and smear-negative cases. Among 47 cytomorphologically non-TBL cases, 15 were positive on Xpert. More than half of Xpert-positive cases were in the range of very low cut-off threshold values (28<Ct<38). Resistance to rifampicin was identified in 4.7% (4/86) of Xpert-positive cases. CONCLUSION: Xpert test showed a high sensitivity and specificity for the diagnosis of TBL on concentrated FNA samples. In addition, Xpert offered rapid detection of rifampicin-resistant M. tuberculosis strains from lymph node aspirates.
Overview
CoChat Summary
TL;DR
This study evaluated GeneXpert MTB/RIF on concentrated fine needle aspirates from 143 presumptive tuberculous lymphadenitis (TBL) cases in Southwest Ethiopia and found high diagnostic accuracy versus a composite bacteriological reference standard. Xpert was much more sensitive than smear microscopy and also detected rifampicin resistance in a small subset of positives.
Key findings
- Among 143 enrolled suspects, 64.3% (92/143) were confirmed TBL cases by the composite reference standard; Xpert detected MTBC in 60.1% (86/143) of presumptive cases.
- Compared with the composite reference standard, Xpert had 87.8% sensitivity (95% CI 81.0–94.5) and 91.1% specificity (95% CI 82.8–99.4).
- Smear microscopy had 27.8% sensitivity, and cytology had 80.0% sensitivity but only 57.8% specificity.
- Rifampicin resistance was identified in 4.7% (4/86) of Xpert-positive cases; 53.5% (46/86) of Xpert-positive samples were “very low” and 44.2% (38/86) were “low” semi-quantitative categories.
Methods
- Prospective diagnostic study at Jimma University Specialized Hospital, Southwest Ethiopia; 143 consecutive outpatients clinically suspected of TBL were enrolled between May and September 2013.
- Fine needle aspirates were split for cytology, Ziehl-Neelsen smear microscopy, Löwenstein-Jensen culture, and Xpert MTB/RIF after NALC/NaOH concentration and centrifugation; Capilia TB-Neo was used to distinguish MTBC from NTM.
- Diagnostic performance was assessed using composite bacteriological methods (culture and/or smear microscopy) as the reference standard, with sensitivity, specificity, and predictive values calculated in SPSS.
Limitations
- The paper states that culture on LJ medium and/or smear microscopy is not sufficient to detect all TBL cases, so the reference standard could miss true cases.
- The authors note they did not include clinical outcomes, and they suggest future studies using liquid culture, histology, and/or clinical response to treatment as better standards.
- They cultured only one NTM isolate and did not speciate it, so the study cannot assess the contribution of NTM lymphadenitis in Ethiopia.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 1 Not valid · 8 Not checked · 63 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
§ GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings > Discussion
What the sources say
- Not checked — no full text of the sourcecites [13] F Biadglegne, 2014, Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia, Tuberculosis source
- Disputedcites [14] D Hillemann, 2011, Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system, Journal of clinical microbiology sourceExperimental — accuracy not yet measured
The Results section on RMP resistance detection reports that all 29 isolates were phenotypically susceptible; among 26 determinate Xpert results, 25 agreed and one indicated resistance. The Discussion explicitly says no rifampin-resistant strain was isolated, so this study could not establish 98–100% agreement for detecting resistant strains. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [18] D Helb, 2010, Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology, Journal of clinical microbiology source
The Results report that Xpert identified all nine rifampin-resistant cases and classified 54 of 55 phenotypically susceptible cases as susceptible—63 of 64 classifications agreed with conventional susceptibility testing (98.4%). Sequencing suggested that the one discordant conventional result was erroneous; the reported 100% corrected specificity therefore depends on that discrepancy analysis, not agreement with the original phenotypic result. (LLM, conf=0.90)
- Supportedcites [26] CC Boehme, 2010, Rapid molecular detection of tuberculosis and rifampin resistance, New England Journal of Medicine source
The Abstract Results report that Xpert correctly identified 200 of 205 rifampin-resistant patients compared with phenotypic drug-susceptibility testing: 97.6%, or 98% rounded to a whole percentage. This supports the lower end of the 98–100% range attributed collectively to several cited studies; this paper's 100% figure applies only after sequencing resolved discrepancies, not to agreement with phenotypic testing. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The specificity (91%) of the Xpert in the current study was found to be consistent with previous studies reported by others (specificity, 89–99%) [20,21,22], but higher than the study done by Biadigilegn et al (specificity, 69.2%) [13].”
§ GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings > Discussion
What the sources say
- Partly supportedcites [20] CM Denkinger, 2014, Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis, European Respiratory Journal sourceExperimental — accuracy not yet measured
The lymph-node TB section reports pooled Xpert specificity of 93.6% against culture and 99.1% against a composite reference standard; the TB meningitis section reports 97.8% against culture. These findings broadly support a comparison with high specificities in previous studies, but this paper does not report the cited 89–99% range. The 91% figure belongs to the citing authors’ current study, not this source. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [21] E Penz, 2015, Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: A meta-analysis, The International Journal of Tuberculosis and Lung Disease source
- Supportedcites [22] LJ Ligthelm, 2011, Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens, Journal of clinical microbiology source
The Results (p. 3968) report Xpert specificity of 88.9%, which rounds to 89% and falls within the cited range. The 91% figure describes the citing authors’ current study, not a result attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the sensitivity of Xpert in the current study is lower than what was found in similar study by Ligthelm et al (sensitivity, 96.7%) [22].”
§ GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings > Discussion
What the sources say
- Supportedcites [22] LJ Ligthelm, 2011, Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens, Journal of clinical microbiology source
The Results (p. 3968) report that Xpert MTB/RIF identified 29 of 30 TB cases against the study’s reference standard, giving a sensitivity of 96.7%. The comparison with the citing authors’ current study is their own, not a result attributed to Ligthelm et al. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
§ GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings > Discussion
What the sources say
- Supportedcites [14] D Hillemann, 2011, Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system, Journal of clinical microbiology source
The Results report 98.2% overall specificity, and the Discussion says the closed reaction chamber makes Xpert less prone to contamination. For seven Xpert-positive, culture-negative patients, the Discussion reports two with TB confirmed by other cultures and two with previously culture-confirmed TB, supporting the cautious inference that such results may be genuine; it also notes that three discrepancies could not be resolved. (LLM, conf=0.84)
- Supportedcites [18] D Helb, 2010, Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology, Journal of clinical microbiology source
The Results report 100% specificity in the clinical validation sample and describe two Xpert-positive, initially culture-negative sputum samples from patients whose second samples were culture-positive. The Discussion says closed cartridges mitigate false positives caused by carryover contamination. Together, these passages support the qualified claim that such cases are likely to be true TB positives. (LLM, conf=0.90)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
§ GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings > Discussion
What the sources say
- Not checked — no full text of the sourcecites [9] SM Al-Ateah, 2012, Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert® system, Saudi medical journal source
- Supportedcites [18] D Helb, 2010, Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology, Journal of clinical microbiology source
The Results section states that Xpert MTB/RIF’s limit of detection in sputum was at least two orders of magnitude more sensitive than the AFB smear. The clinical validation results also report Xpert detection in culture-positive, smear-negative samples. (LLM, conf=0.94)
- Supportedcites [22] LJ Ligthelm, 2011, Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens, Journal of clinical microbiology source
In the Results (p. 3968), Xpert identified 29 of 30 TB cases and was positive in all six smear-negative, culture-positive cases. These findings support higher sensitivity than smear microscopy for the fine-needle-aspiration specimens studied. (LLM, conf=0.90)
plainstates an associationn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 77 claims and every source verdict.
- It may state two separate claims as one. 18
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This finding is lower than another study from Ethiopia done by Mulualem et al (sensitivity, 87.8%) [29].”
From Diagnostic accuracy of Xpert MTB/RIF assay and non-molecular methods for the diagnosis of tuberculosis lymphadenitis (2019) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, cytology lacks specificity but has high sensitivity [31,32].”
From Diagnostic accuracy of Xpert MTB/RIF assay and non-molecular methods for the diagnosis of tuberculosis lymphadenitis (2019) · cites this paper as [32]
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 1×
“Previous studies reported 98– 100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527 · cited 2×
“The specificity (91%) of the Xpert in the current study was found to be consistent with previous studies reported by others (specificity, 89–99%) [20,21,22], but higher than the study done by Biadigilegn et al (specificity, 69.”
ResultRapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System
Hillemann, D., Rüsch-Gerdes, S., Boehme, C., & Richter, E. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02268-10 · Cited by 413
Identification of the Causative Organism of Tuberculous Lymphadenitis in Ethiopia by PCR
Kidane, D., Olobo, J. O., Habte, A., Negesse, Y., Aseffa, A., Abate, G., Yassin, M. A., Bereda, K., & Harboe, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.11.4230-4234.2002 · Cited by 126 · cited 1×
“Cytology and conventional smear microscopy have been used as the initial diagnostic tools for TBL in resource poor settings [4,5].”
MethodLigthelm, L. J., Nicol, M. P., Hoek, K. G. P., Jacobson, R., van Helden, P. D., Marais, B. J., Warren, R. M., & Wright, C. A. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01310-11 · Cited by 123 · cited 2×
“The specificity (91%) of the Xpert in the current study was found to be consistent with previous studies reported by others (specificity, 89–99%) [20,21,22], but higher than the study done by Biadigilegn et al (specificity, 69.”
ResultA multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay
Blakemore, R., Nabeta, P., Davidow, A. L., Vadwai, V., Tahirli, R., Munsamy, V., Nicol, M., Jones, M., Persing, D. H., Hillemann, D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0536oc · Cited by 118
Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis
Penz, E., Boffa, J., Roberts, D. J., Fisher, D., Cooper, R., Ronksley, P. E., & James, M. T. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0262 · Cited by 97 · cited 2×
“The specificity (91%) of the Xpert in the current study was found to be consistent with previous studies reported by others (specificity, 89–99%) [20,21,22], but higher than the study done by Biadigilegn et al (specificity, 69.”
Result(1992) · PubMed · Cited by 88
Wright, C. A., van der Burg, M., Geiger, D., Noordzij, J. G., Burgess, S. M., & Marais, B. J. (2008) · Diagnostic Cytopathology · doi:10.1002/dc.20788 · Cited by 84 · cited 3×
“FNA cytology as an inexpensive and reliable tool for TBL has been studied by a number of investigators [4,24,25].”
BackgroundMethod
Cited by
Xpert ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
Kohli, M., Schiller, I., Dendukuri, N., Dheda, K., Denkinger, C. M., Schumacher, S. G., & Steingart, K. R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012768.pub2 · Cited by 245
Kohli, M., Schiller, I., Dendukuri, N., Yao, M., Dheda, K., Denkinger, C. M., Schumacher, S. G., & Steingart, K. R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012768.pub3 · Cited by 215
Kay, A. W., Fernández, L. G., Takwoingi, Y., Eisenhut, M., Detjen, A., Steingart, K. R., & Mandalakas, A. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013359.pub2 · Cited by 154
Ganchua, S. K. C., Cadena, A. M., Maiello, P. A., Gideon, H. P., Myers, A. J., Junecko, B. A. F., Klein, E. C., Lin, P. L., Mattila, J. T., & Flynn, J. L. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007337 · Cited by 90
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
Kay, A. W., Ness, T. E., Verkuijl, S. E., Viney, K. A., Brands, A., Masini, T., Fernández, L. G., Eisenhut, M., Detjen, A., Mandalakas, A. M., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013359.pub3 · Cited by 122
Metadata
- Authors
- Tadesse, M., Abebe, G., Abdissa, K., Aragaw, D., Abdella, K., Bekele, A., Bezabih, M., Apers, L., de Jong, B. C., & Rigouts, L.
- Affiliations
- Jimma University (ET)
- Instituut voor Tropische Geneeskunde (BE)
- University of Antwerp (BE)
- Corresponding author
- Abebe, Gemeda
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-09-14
- Volume
- 10
- Issue
- 9
- Pages
- e0137471
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4569183
- OpenAlex
- W2191708934
- Semantic Scholar
- e6b6ebca5ff60c1d002d5d070d66a0ec638fbe68
- Cited by
- 85
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 10 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 12 · 2019: 7 · 2018: 10 · 2017: 6 · 2016: 5
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Jimma University
- Vlaamse Interuniversitaire Raad
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Keywords
- tuberculous lymphadenitis, Xpert MTB/RIF, extrapulmonary tuberculosis, Mycobacterium tuberculosis complex, smear microscopy, cytology, sensitivity and specificity, rifampicin resistance, nontuberculous mycobacteria, Ethiopia, molecular tuberculosis diagnosis, N-acetylcysteine
- MeSH terms
- Adolescent, Adult, Bacteriological Techniques, Ethiopia, Female, Humans, Lymph Nodes, Male, Middle Aged, Mycobacterium tuberculosis, Prognosis, Rifampin, Sputum, Tuberculosis, Lymph Node, Biopsy, Fine-Needle, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings. https://app.cochat.ai/papers/10.1371/journal.pone.0137471
- The paper
- Tadesse, M., Abebe, G., Abdissa, K., Aragaw, D., Abdella, K., Bekele, A., Bezabih, M., Apers, L., de Jong, B. C., & Rigouts, L. (2015). GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings. PLoS ONE. https://doi.org/10.1371/journal.pone.0137471
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
